Skip to main content
PMC home page
Cell Death & Disease logoLink to Cell Death & Disease
. 2014 May 22;5(5):e1250. doi: 10.1038/cddis.2014.227

Altered expression of Alzheimer's disease-related genes in the cerebellum of autistic patients: a model for disrupted brain connectome and therapy

F Zeidán-Chuliá 1,*, B-HN de Oliveira 1, A B Salmina 2, M F Casanova 3, D P Gelain 1, M Noda 4, A Verkhratsky 5,6,7, J CF Moreira 1
PMCID: PMC4047885  PMID: 24853428

Abstract

Autism and Alzheimer's disease (AD) are, respectively, neurodevelopmental and degenerative diseases with an increasing epidemiological burden. The AD-associated amyloid-β precursor protein-α has been shown to be elevated in severe autism, leading to the ‘anabolic hypothesis' of its etiology. Here we performed a focused microarray analysis of genes belonging to NOTCH and WNT signaling cascades, as well as genes related to AD and apoptosis pathways in cerebellar samples from autistic individuals, to provide further evidence for pathological relevance of these cascades for autism. By using the limma package from R and false discovery rate, we demonstrated that 31% (116 out of 374) of the genes belonging to these pathways displayed significant changes in expression (corrected P-values <0.05), with mitochondria-related genes being the most downregulated. We also found upregulation of GRIN1, the channel-forming subunit of NMDA glutamate receptors, and MAP3K1, known activator of the JNK and ERK pathways with anti-apoptotic effect. Expression of PSEN2 (presinilin 2) and APBB1 (or F65) were significantly lower when compared with control samples. Based on these results, we propose a model of NMDA glutamate receptor-mediated ERK activation of α-secretase activity and mitochondrial adaptation to apoptosis that may explain the early brain overgrowth and disruption of synaptic plasticity and connectome in autism. Finally, systems pharmacology analyses of the model that integrates all these genes together (NOWADA) highlighted magnesium (Mg2+) and rapamycin as most efficient drugs to target this network model in silico. Their potential therapeutic application, in the context of autism, is therefore discussed.

Keywords: proliferation, mitochondria, APP, magnesium, rapamycin

Autism is a neurodevelopmental disorder characterized by specific activity patterns and aberrant social interaction and communication.1 Genetic and environmental factors have been proposed to account for apparently increasing rates of autism diagnostics.2, 3 Its neurobiological basis is, however, poorly understood and the behavioral phenotypes display a high grade of heterogeneity, leading to the definition of ‘autism spectrum disorders' (ASDs). It has been reported that clinical onset of ASD seems to be preceded by a phase of brain overgrowth in the first years of life followed by decreased growth rates between 5 and 12 years of age, when compared with controls.4 These abnormalities are paralleled by higher levels of brain-derived neurotrophic factor, insulin growth factors 1 and 2 (IGF-1 and IGF-2), IGF-binding protein 3, growth hormone-binding protein, neurotrophin-4, and a neuroinflammatory response in the ASD brains.5, 6, 7, 8 Changes in trophic support may account for abnormal brain growth and an altered connectome, thus defining multiple ASD symptoms. Recent pieces of evidence also indicate the role for deregulated processing of the Alzheimer's disease (AD)-associated amyloid-β (Aβ) precursor protein (APP) in ASD-associated pathology. Aβ is considered to be central for the pathophysiology of AD, which in its genetic and sporadic forms appears to be the most common cause of age-associated dementia. AD is characterized by specific pathological hallmarks represented by extracellular deposits of fibrillar Aβ, intraneuronal accumulation of neurofibrillary tangles due to hyperphosphorylation of cytoskeletal Tau filaments, as well as impairment of neurogenesis. The end result is massive neuronal death and consequent decline in cognitive functions.9, 10, 11 In ASD, the AD-associated APP, in particular its neuroprotective processing product or secreted APPα (sAPPα), was found to be elevated.12 Current research indicates that abnormalities of the cerebellum, now believed to have a role in cognitive function, are associated with autism; being one of the brain regions where cellular and growth abnormalities are most pronounced in the disorder.13, 14, 15

Here we address the question of whether changes of expression in the same set of genes observed in AD neuropathology could also be found in autism; and if this is the case, whether drugs tested not only in the context of autism but also in AD may be considered for therapeutics in these patients. Our study shows altered expression of genes belonging to NOTCH, WNT, AD, and apoptosis pathways in cerebellar samples from autistic individuals. In addition, systems pharmacology analyses of such a pathway that integrates NOTCH, WNT, AD, and apoptosis-related genes suggest magnesium (Mg2+) and rapamycin for further therapeutic exploration in the context of autism; two compounds/drugs that therapeutic use have already been discussed for different AD models.16, 17

Results

Subnetwork analyses of AD-related pathways reveal transcriptional changes in the cerebellum of autistic individuals

For analyzing the potential transcriptional changes in genes belonging to pathways typically associated to AD pathology in autism, we constructed four subnetworks models of NOTCH (Supplementary Figure S1A), WNT (Supplementary Figure S2A), AD (Figure 1a), and apoptosis (Supplementary Figure S3A) pathways. These subnetworks contained 41, 136, 171, and 70 respective genes/proteins (Supplementary Tables S1–S4). Next, we performed a focused microarray analysis of the genes belonging to each subnetwork by using samples from the cerebellum of autistic patients versus controls. In 31% (116 out of 374) of the genes belonging to these in silico models were differentially expressed in ASD samples (corrected P-value <0.05) (Table 1). More specifically, ∼30% for NOTCH (12 genes), ∼23% for WNT (31 genes), >40% for AD (69 genes), and ∼26% for apoptosis (18 genes). UQCRC1, NDUFS3, NDUFA9, JUN, CIDEB, CDC42, NDUFA6, NDUFB7, NDUFA1, and COX4I1 (Table 1) were the top 10 genes that displayed most significant changes in their expression. The downregulated genes were cytochrome c reductase and NADH dehydrogenase related. Among the AD-related genes, upregulation of GRIN1, the channel-forming subunit of NMDA glutamate receptors, and MAP3K1, known activator of JNK and ERK pathways with anti-apoptotic effect, were also found together with significantly lower expression of presinilin 2 (PSEN2) and APBB1 (Table 1).

Figure 1.

Figure 1

Open in a new tab

AD subnetwork analysis. (a) General landscape of interactions between genes/proteins belonging to the AD pathway (map05010; KEGG Pathway; http://www.genome.jp/kegg/pathway.html). The in silico network model was developed by using the STRING 9.05 database resource search tool, under a confidence score of 0.600 and using ‘Databases' and ‘Experiments' as input options. (b) Focused microarray analyses of AD-related genes in the cerebellum of autistic patients versus healthy controls over the in silico model. The z axis for representing the relative gene expression was constructed by using the ViaComplex software

Table 1. Differentially expressed genes from the NOTCH, WNT, Alzheimer's disease, and apoptosis subnetworks in the cerebellum of autistic patients.

Gene symbol Alias and/or description Ensembl ID (ENSP) Differential gene expression (Up/down) Corrected P-value (FDR) Subnetwork contribution/s
UQCRC1 Ubiquinol–cytochrome c reductase core protein I ENSP00000203407 Down 0.001062657 AD
NDUFS3 NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30 kDa (NADH-coenzyme Q reductase) ENSP00000263774 Down 0.001722868 AD
NDUFA9 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39 kDa ENSP00000266544 Down 0.00179604 AD
JUN Jun oncogene ENSP00000360266 Up 0.001921098 WNT
CIDEB Cell death-inducing DFFA-like effector b ENSP00000258807 Down 0.001949191 APO
CDC42 Cell division cycle 42 (GTP-binding protein, 25 kDa) ENSP00000314458 Down 0.002000135 WNT
NDUFA6 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6, 14 kDa ENSP00000330937 Down 0.002033295 AD
NDUFB7 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7, 18 kDa ENSP00000215565 Down 0.002205663 AD
NDUFA1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 7.5 kDa ENSP00000360492 Down 0.002205663 AD
COX4I1 Cytochrome c oxidase subunit IV isoform 1 ENSP00000253452 Down 0.002246413 AD
NCSTN Nicastrin ENSP00000294785 Up 0.002354256 AD NOT
UQCRC2 Ubiquinol–cytochrome c reductase core protein II ENSP00000268379 Down 0.002354256 AD
NDUFS4 NADH dehydrogenase (ubiquinone) Fe-S protein 4, 18 kDa (NADH-coenzyme Q reductase) ENSP00000296684 Down 0.002459308 AD
CYC1 Cytochrome c-1 ENSP00000317159 Down 0.002656014 AD
COX8A Cytochrome c oxidase subunit 8A (ubiquitous) ENSP00000321260 Down 0.002656014 AD
NDUFB4 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 4, 15 kDa ENSP00000184266 Down 0.002688877 AD
EIF2AK2 Eukaryotic translation initiation factor 2-alpha kinase 2 ENSP00000233057 Up 0.002850857 AD
BID BH3-interacting domain death agonist ENSP00000318822 Down 0.002892499 AD APO
NDUFA4 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4, 9 kDa ENSP00000339720 Down 0.003092192 AD
WNT3 Wingless-type MMTV integration site family, member 3 ENSP00000225512 Up 0.003122302 WNT
NDUFAB1 NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1, 8 kDa ENSP00000007516 Down 0.003262718 AD
NDUFA11 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 11, 14.7 kDa ENSP00000311740 Down 0.003262718 AD
COX5A Cytochrome c oxidase subunit Va ENSP00000317780 Down 0.003530677 AD
PRKCA Protein kinase C, alpha ENSP00000284384 Up 0.003532751 APO WNT
NDUFB9 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9, 22 kDa ENSP00000276689 Down 0.003532751 AD
NDUFA2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, 8 kDa ENSP00000252102 Down 0.003622328 AD
COX5B Cytochrome c oxidase subunit Vb ENSP00000258424 Down 0.003627494 AD
BCL2 B-cell CLL/lymphoma 2 ENSP00000329623 Up 0.003686548 APO
PRICKLE2 Prickle homolog 2 (Drosophila) ENSP00000295902 Up 0.003858642 WNT
SDHB Succinate dehydrogenase complex, subunit B, iron–sulfur (Ip) ENSP00000364649 Down 0.003949261 AD
NDUFA10 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 10, 42 kDa ENSP00000252711 Down 0.004023111 AD
NDUFB2 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 8 kDa ENSP00000247866 Down 0.00417954 AD
NDUFB6 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17 kDa ENSP00000369176 Down 0.00420016 AD
NDUFA7 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7, 14.5 kDa ENSP00000301457 Down 0.004449939 AD
NDUFB3 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3, 12 kDa ENSP00000237889 Down 0.004449939 AD
UQCRB Ubiquinol–cytochrome c reductase-binding protein ENSP00000287022 Down 0.004918915 AD
NCOR2 Nuclear receptor co-repressor 2 ENSP00000348551 Up 0.005223194 NOT
LRP5 Low density lipoprotein receptor-related protein 5 ENSP00000294304 Up 0.005717875 WNT
BAD BCL2-associated agonist of cell death ENSP00000309103 Down 0.005763042 AD APO
UQCRH Ubiquinol–cytochrome c reductase hinge protein ENSP00000309565 Down 0.005906155 AD
PSEN2 Presenilin 2 (Alzheimer disease 4) ENSP00000355747 Down 0.005968353 AD NOT
NDUFA13 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13 ENSP00000380364 Down 0.00609761 AD
NDUFB10 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10, 22 kDa ENSP00000268668 Down 0.006262982 AD
COX6C Cytochrome c oxidase subunit VIc ENSP00000297564 Down 0.006681564 AD
UQCRQ Ubiquinol–cytochrome c reductase, complex III subunit VII, 9.5 kDa ENSP00000367934 Down 0.00745614 AD
NDUFA3 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 9 kDa ENSP00000398290 Down 0.007600014 AD
HEY1 Hairy/enhancer-of-split related with YRPW motif 1 ENSP00000338272 Down 0.00784934 NOT
DAAM1 Disheveled associated activator of morphogenesis 1 ENSP00000247170 Up 0.007909188 WNT
PPP3CC Protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform ENSP00000240139 Down 0.008118636 AD APO WNT
COX7B Cytochrome c oxidase subunit VIIb ENSP00000417656 Down 0.008265168 AD
NDUFB11 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 11, 17.3 kDa ENSP00000276062 Down 0.008503556 AD
NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 ENSP00000226574 Up 0.008570685 APO
KAT2B K(lysine) acetyltransferase 2B ENSP00000263754 Up 0.009111103 NOT
NDUFA12 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12 ENSP00000330737 Down 0.009479959 AD
UQCRFS1 Ubiquinol–cytochrome c reductase, Rieske iron–sulfur polypeptide 1 ENSP00000306397 Down 0.009524703 AD
NDUFS5 NADH dehydrogenase (ubiquinone) Fe-S protein 5, 15 kDa (NADH-coenzyme Q reductase) ENSP00000362058 Down 0.009998423 AD
BAX BCL2-associated X protein ENSP00000293288 Down 0.010349538 APO
CYCS Cytochrome c, somatic ENSP00000307786 Down 0.010843806 AD
NDUFV1 NADH dehydrogenase (ubiquinone) flavoprotein 1, 51 kDa ENSP00000322450 Down 0.011017543 AD
RBX1 Ring-box 1 ENSP00000216225 Down 0.01185897 WNT
NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha ENSP00000216797 Up 0.012804007 AD APO
AXIN2 Axin 2 ENSP00000302625 Up 0.01310984 WNT
CSNK1G1 Casein kinase 1, gamma 1 ENSP00000305777 Up 0.013381084 WNT
NDUFS8 NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23 kDa (NADH-coenzyme Q reductase) ENSP00000315774 Down 0.014197263 AD
HSD17B10 Hydroxysteroid (17-beta) dehydrogenase 10 ENSP00000168216 Down 0.014254764 AD
RAC3 Ras-related C3 botulinum toxin substrate 3 (rho family, small GTP-binding protein Rac3) ENSP00000304283 Down 0.014704894 WNT
DTX3 Deltex homolog 3 (Drosophila) ENSP00000338050 Down 0.015144277 NOT
CDK5 Cyclin-dependent kinase 5 ENSP00000297518 Down 0.015567567 AD
CABIN1 Calcineurin-binding protein 1 ENSP00000263119 Up 0.015953582 AD WNT
COX7C Cytochrome c oxidase subunit VIIc ENSP00000247655 Down 0.016686515 AD
RUVBL1 RuvB-like 1 (Escherichia coli) ENSP00000318297 Down 0.016765972 WNT
DFFA DNA fragmentation factor, 45 kDa, alpha polypeptide ENSP00000366237 Up 0.017000844 APO
NDUFB8 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8, 19 kDa ENSP00000299166 Down 0.01782766 AD
COX6B1 Cytochrome c oxidase subunit VIb polypeptide 1 (ubiquitous) ENSP00000246554 Down 0.017845204 AD
TLE1 Transducin-like enhancer-of-split 1 (E(sp1) homolog, Drosophila) ENSP00000365682 Up 0.018030294 NOT
NOTCH1 Notch homolog 1 ENSP00000277541 Up 0.018222797 AD NOT
RYR2 Ryanodine receptor 2 (cardiac) ENSP00000355533 Up 0.019085894 AD
CACYBP Calcyclin-binding protein ENSP00000356652 Down 0.02050623 WNT
CSNK2B Casein kinase 2, beta polypeptide ENSP00000415615 Down 0.02050623 WNT
SENP2 SUMO1/sentrin/SMT3 specific peptidase 2 ENSP00000296257 Up 0.021603075 WNT
CHD8 Chromodomain helicase DNA-binding protein 8 ENSP00000406288 Up 0.021898019 WNT
DTX2 Deltex homolog 2 (Drosophila) ENSP00000322885 Up 0.022277856 NOT
SDHC succinate dehydrogenase complex, subunit C, integral membrane protein, 15 kDa ENSP00000356953 Down 0.023024554 AD
LRP1 Prolow-density lipoprotein receptor-related protein 1 Precursor (LRP) ENSP00000243077 Up 0.023159082 AD
DLL1 Delta-like 1 (Drosophila) ENSP00000355718 Up 0.023184387 NOT
APBB1 Amyloid beta (A4) precursor protein binding, family B, member 1 (Fe65) ENSP00000299402 Down 0.024237411 AD
MAP3K7 Mitogen-activated protein kinase kinase kinase 7 ENSP00000358335 Down 0.02453243 WNT
NDUFC2 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 2, 14.5 kDa ENSP00000281031 Down 0.025489098 AD
APLP1 Amyloid beta (A4) precursor-like protein 1 ENSP00000221891 Up 0.026382742 AD
BIRC2 Baculoviral IAP repeat-containing 2 ENSP00000227758 Down 0.026521867 APO
NDUFB5 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5, 16 kDa ENSP00000259037 Down 0.027921676 AD
PPARD Peroxisome proliferator-activated receptor delta ENSP00000310928 Up 0.029747209 WNT
SKP1 S-phase kinase-associated protein 1 ENSP00000231487 Down 0.03098415 WNT
PRKCB Protein kinase C, beta ENSP00000305355 Down 0.031488508 WNT
CTNNBIP1 Catenin, beta-interacting protein 1 ENSP00000366466 Down 0.031553064 WNT
RCAN1 Regulator of calcineurin 1 ENSP00000320768 Down 0.031896183 AD
AIFM1 Apoptosis-inducing factor, mitochondrion-associated, 1 ENSP00000287295 Down 0.031972517 APO
CALM2 Calmodulin 2 (phosphorylase kinase, delta) ENSP00000272298 Down 0.032263251 AD
CAMK2D Calcium/calmodulin-dependent protein kinase II delta ENSP00000339740 Up 0.034576294 WNT
SMG7 Smg7 homolog, nonsense-mediated mRNA decay factor (Caenorhabditis elegans) ENSP00000340766 Up 0.034586995 APO
TBL1X Transducin (beta)-like 1X-linked ENSP00000217964 Up 0.036511455 WNT
CASP3 Caspase 3, apoptosis-related cysteine peptidase ENSP00000311032 Up 0.037829198 AD APO
FRAT2 Frequently rearranged in advanced T-cell lymphomas 2 ENSP00000360058 Up 0.037835094 WNT
TCF7L2 Transcription factor 7-like 2 (T-cell specific, HMG-box) ENSP00000358404 Up 0.03801246 WNT
PRICKLE1 Prickle homolog 1 (Drosophila) ENSP00000345064 Up 0.038401928 WNT
MAP3K1 Mitogen-activated protein kinase kinase kinase 1 ENSP00000382423 Up 0.038406592 AD
MAML1 Mastermind-like 1 (Drosophila) ENSP00000292599 Up 0.038709571 NOT
GRIN1 Glutamate receptor, ionotropic, N-methyl D-aspartate 1 ENSP00000360616 Up 0.03916101 AD
SNCA Synuclein, alpha (non A4 component of amyloid precursor) ENSP00000338345 Down 0.040205801 AD
IKBKG Inhibitor of kappa light polypeptide gene enhancer in B cells, kinase gamma ENSP00000358622 Down 0.04087009 APO
PRKCZ Protein kinase C, zeta ENSP00000367830 Down 0.041055303 WNT
EP300 MicroRNA 1281 ENSP00000263253 Up 0.041373019 NOT WNT
ENDOG Endonuclease G ENSP00000361725 Down 0.042737537 APO
PPP3CB Protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform ENSP00000378306 Down 0.046120071 AD APO WNT
BCL2L1 BCL2-like 1 ENSP00000302564 Up 0.046646273 APO
NDUFV2 NADH dehydrogenase (ubiquinone) flavoprotein 2, 24 kDa ENSP00000327268 Down 0.046908433 AD
Open in a new tab

Corrected P-values <0.05 were considered significant. ‘NOT', ‘WNT', ‘AD', and ‘APO' represent NOTCH, WNT, Alzheimer's disease, and apoptosis subnetworks, respectively

The in silico models were subsequently subjected to further analysis with the ViaComplex software that plots the expression mean values derived from each diseased sample (autism) over the expression of healthy control samples (z axis) in the network model (NOTCH, WNT, AD, and apoptosis), presenting them as two-dimensional (2D) ViaComplex-generated landscapes (Supplementary Figures S1B–S3B; and Figure 1b). The generated plot visualizes the general landscape of gene expression of diseased samples (autism) versus healthy controls for each subnetwork. Expression levels are color coded with warm colors (yellow to red) being indicative of increased expression, whereas cold (green to blue) colors indicate decreased gene expression when compared with control samples. The 2D ViaComplex plots revealed a general upregulation of NOTCH pathway (Supplementary Figure S1B) and specific decrease in the expression of mitochondria-related genes (network cluster on the upper left; Figure 1b).

NOWADA is an integrative network model for NOTCH, WNT, AD, and apoptosis subnetworks

As results presented above showed significant changes in expression of genes belonging to NOTCH, WNT, AD, and apoptosis pathways in cerebellar brain biopsies from ASD patients, our next aim was to test the feasibility of an in silico model that is able to integrate these four subnetworks into one single network and therefore to characterize the relevant molecular route. The Venn diagram, which visualizes the level of subnetwork information integration (Figure 2), shows that the four subnetworks contain common nodes (genes/proteins) allowing communication with one another. Then, by using STRING 9.05 (‘Experiments' and ‘Databases' confidence score of 0.600) and plotting with Cytoscape software, we developed a NOTCH-WNT-Alzheimer's Disease-Apoptosis (NOWADA) gene/protein interaction network model able to characterize in silico these molecular interactions (Figure 3). The model is composed of 374 genes/proteins interconnecting through 3665 interactions, with only five nodes (PPP3CA, PPP3CB, PPP3CC, PPP3R1, and PSEN1) contributing to maximum three groups (NOTCH, WNT, AD, or apoptosis subnetworks) at the same time.

Figure 2.

Figure 2

Open in a new tab

Venn diagram showing information integration from the studied subnetworks. NOTCH, WNT, AD, and apoptosis models contain common nodes (genes/proteins) with, at least, one subnetwork

Figure 3.

Figure 3

Open in a new tab

Network model of interactions between genes/protein belonging to NOTCH, WNT, AD, and apoptosis subnetworks (NOWADA network). The present model was developed by using the STRING 9.05 database resource search tool, under a confidence score of 0.600, and by using ‘Databases' and ‘Experiments' as input options and visualized by plotting it with Cytoscape software. The number of subnetwork contributions of each gene/protein within the network is represented in the figure as indicated in the inset

Identification of hey hub genes/proteins within NOWADA network in the context of autism

In order to describe the global characteristics of the network, we measured centralities18 or topological network properties as follows: (i) ‘stress', representing how much a node (gene/protein) is traversed by a high number of ideal routes or short paths in a network. Then, a gene/protein traversed by higher number of short paths will be, by definition, more stressed. (ii) ‘connectivity or degree' that quantifies the local topology of each node by summing up the number of its adjacent nodes. (iii) ‘Betweenness', which is similar to stress as a topological network property, provides a more informative and elaborated centrality index as it measures how frequently the shortest path, connecting every pair of nodes, is going through a third given node. In other words, both ‘stress' and ‘betweenness' give information about the influence of a node over the spread of information throughout the network. (iv) Finally ‘closeness', defined by the inverse of the average length of the shortest paths to access all other proteins in the network, gives an idea about the level of proximity of a node to other nodes or how long it will take the information to spread from a given node to other nodes in the network. Logically, the larger the value, the faster the information spreads. Our focus in this part of the study is to target vulnerable (central) components in NOWADA network with 31% of its genes displaying significant changes in expression in the cerebellum of autistic patients (corrected P-values <0.05). Upon calculation of each centrality value for each gene/protein (Supplementary Table S5), we identified the hub-bottlenecks (HBs) of the network that also displayed higher values of ‘stress' and closeness centralities. These network nodes were (in alphabetical order) APP, CALM1, CASP3, CTNNB1, DVL2, DVL3, EP300, FZD5, GSK3B, MYC, NOTCH1, PLCB2, PRKCA, and TP53 (Supplementary Table S6 and Figure 4). As central members, these genes/proteins will control the flow of biological information within the network and its disruption (e.g., by drug interaction) could destroy the entire network into small components. Remarkably, CTNNB1, gene encoding for β-catenin protein (Supplementary Table S2), was the node with top values for all the measured centralities (Supplementary Table S6 and Figure 4).

Figure 4.

Figure 4

Open in a new tab

Analysis of the topological properties (a–c) of genes/proteins belonging to the network (NOWADA). Dashed lines are indicating the threshold value for each property. Upregulated and downregulated genes in the subnetwork are marked with red and blue triangles, respectively, as indicated in the inset. Note that NH-Bs and HBs distinguish non-HBs from HBs, respectively

Systems pharmacology analysis of NOWADA network suggests Mg2+ and rapamycin as most efficient drugs to target the model in silico

Previous analysis allowed us to identify central nodes (bottlenecks) with high topological network values. At this stage, as NOWADA network can be considered as a common pathway model for AD and autism, these 14 nodes (genes/proteins) could represent potential targets for both pathologies in silico. With the aim of elucidating the most suitable and efficient drugs targeting the network in the context of autism, differential gene expression values were taken into account. Our selection criteria was then as follows: (i) to select drugs targeting higher number of genes/proteins within the network; (ii) from those, to choose the drugs affecting/associated to higher numbers of bottlenecks (preferably, HBs with high values of ‘stress' and ‘closeness' centralities); and (iii) to select drugs that targets, within the network (NOWADA), include higher number of genes with significant changes in expression. Upon systematic review of the literature (see Materials and Methods section), 47 used/proposed drugs for autism therapy were divided in 15 groups and tested for potential interaction/s with genes/proteins of the network model. The groups are acetylcholinesterase inhibitors, allosteric modulators of metabotropic glutamate receptors, antidepressants (SSRI and tricyclic), antiepileptics/anticonvulsants, antiopioids, antipsychotics, complementary and alternative medicines, inhibitors of mTOR, neurohormones, NMDAR (agonists and antagonists), mood stabilizers, psycoestimulants, and sympatholytic medications. Incidentally, 36 out of the 47 autism-related drugs have already been studied in different models of AD (in humans or in vivo) for potential therapeutic use19, 20, 21, 22 (Supplementary Table S7). Upon using STITCH 3.1, we confirmed that 16 out of the 47 tested drugs had positive hits with at least one gene/protein of NOWADA network (with ‘Experiments' and ‘Databases' as input options; confidence score of 0.600). These therapeutic agents were (in alphabetical order) as follows: chlorpromazine, clozapine, D-cycloserine, fluoxetine, galantamine, haloperidol, imipramine, lithium, luteolin, Mg2+, melatonin, memantine, olanzapine, rapamycin, valproic acid, and ziprasidone. Most targeted nodes were GSK3B (glycogen synthase kinase 3β, 6 hits), AKT1 (5 hits), CALM1 (3 hits), GRIN1 (3 hits), GRIN2B (3 hits), CHRNA7 (2 hits), GRIN2A (2 hits), and JUN (2 hits) (Supplementary Table S9). Except for CHRNA7, our systematic review of the literature could confirm the expression of the indicated gene products in neuronal and/or glial cells (astroglia, microglia, and oligodendroglia; Supplementary Table S9), thus representing both neuronal and glial targets. When looking into the characteristics of the tested compounds/drugs–genes/protein interactions, Mg2+ and rapamycin are highlighted as the most efficient drugs in silico to target this disrupted pathway, which is here represented in silico by NOWADA network (Supplementary Table S10). More specifically, Mg2+ interacts with 32 genes/proteins; among those, eight differentially expressed genes in the cerebellum of autistic patients: the upregulated EIF2AK2 (corrected P-value=0.002850857) and CAMK2D (corrected P-value=0.034576294), as well as the downregulated CDC42 (corrected P-value=0.002000135), COX5A (corrected P-value=0.003530677), NDUFV1 (corrected P-value=0.011017543), NDUFS8 (corrected P-value=0.014197263), RAC3 (corrected P-value=0.014704894), and CALM2 (corrected P-value=0.032263251) (Figure 5). In order to elucidate the biological processes that Mg2+ could be influencing in this context, a functional enrichment analysis of the genes belonging to the Mg2+ subnetwork was performed. The top 10 affected processes are as follows: phosphorylation, phosphorus metabolic process or phosphate-containing compound metabolic process, neuromuscular process, regulation of neurological system process, protein amino-acid autophosphorylation, small GTPase-mediated signal transduction, mitochondrial electron transport (NADH to ubiquinone), positive regulation of cell projection organization, and intracellular signaling cascade (corrected P-value <0.05; Supplementary Table S11).

Figure 5.

Figure 5

Open in a new tab

Mg2+ subnetwork analysis. (a) In silico network model of the interactions between Mg2+ and genes/proteins belonging to the network (NOWADA), developed by using STITCH 3.1 with ‘Experiments' and ‘Databases' as input options and a confidence score of 0.600. (b) Actions view representation between the network nodes by ‘catalysis' (yellow). (c) Actions view representation between the network nodes by ‘binding' (white color). (d) Actions view representation between the network nodes by ‘inhibition' (red color). Upregulated and downregulated genes in the subnetwork are marked with red and blue triangles, respectively, as indicated in the inset

Discussion

Here we studied the possible neurobiological mechanism involved in the excessive rates of early brain overgrowth observed in autism4 based on the recent evidence, indicating a possible role for the AD-associated APP processing pathway in ASD.23 Proliferation in the brain results from balancing proliferative rates and developmental apoptosis (i.e., more proliferation and less death will result in a larger brain).24 APP is proteolytically processed by two competing pathways such as the amyloidogenic (β-secretase-mediated) and the non-amyloidogenic (α-secretase-mediated) pathways.25 sAPPβ (secreted APPβ) and the neurotoxic Aβ peptide are generated from APP and released to the extracellular site by proteolytic cleavage of both β- and γ-secretases.26 Aβ has been suggested to have a critical role in neurotoxicity and apoptotic events seen in AD.27 In contrast, the non-amyloidogenic product sAPPα and the p3 peptide are formed by proteolytic cleavage of both α- and γ-secretases26 sAPPα exerts proliferative effects on neural progenitor cells isolated from embryonic brains and is able to enhance synaptogenesis, neurite outgrowth, cell survival, and cell adhesion;28, 29, 30, 31 and APP seems to be able to modulate the neuronal precursors migration.32 As γ-secretase cleaves several proteins that include APP and Notch,33 the potential role of NOTCH signaling pathway in the genesis of AD is also considered.34 Focused microarray analysis used in this study demonstrated that expression of 40% of the AD-related genes was altered in the cerebellum of autistic patients (corrected P-value <0.05), these changes mainly represented by downregulation of NADH dehydrogenases and cytochrome c oxidases (Table 1). These results reflect deficient mitochondrial respiratory chain that is consistent with recent reports describing mitochondrial dysfunction in ASD;35 or may indirectly confirm tight Notch–mitochondria interconnections.36 An upregulation of GRIN1 (corrected P-value=0.03916101), the channel-forming subunit NR1 of NMDA glutamate receptors and MAP3K1 (corrected P-value=0.038406592), also known as MEKK1 or MAPK/ERK Kinase Kinase 1, which activates JNK and ERK pathways with anti-apoptotic effect,37 were also found among the AD-related genes in ASD samples (Table 1). In vivo studies have shown that stressful events during gestation can increase the expression of NMDA receptors in the brain.38 The altered expression of NMDA receptors may be related to epigenetic regulation (e.g., DNA hypomethylation) because histone lysine methylation at gene promoters is involved in developmental regulation and maintenance of region-specific expression patterns of ionotropic and metabotropic glutamate receptors in the brain.39 Furthermore, glutamate receptors expression and/or their activity can modulate the APP processing mechanisms.40 High glutamate receptors activation and consequent increase in intracellular calcium activate the ERK signaling cascade, enhancing α-secretase cleavage of APP, and thus reducing APP processing into Aβ. An increase in α-secretase activity may lead to higher production of sAPPα.26 In this study, we hypothesize that deregulated glutamatergic synaptic transmission/plasticity, caused by increased expression of GRIN1 and hence increased density of NMDA receptors, may affect neuronal growth in autism by shifting APP processing to the production of sAPPα through ERK-mediated α-secretase activity. SAPPα, in turn, may facilitate proliferation by activating the PI3K/Akt/mTOR pathway.41, 42 Based on the present data and existing literature, we proposed this model (Figure 6) as a mechanism that could explain the focal modification of neurogenesis, migration, and alterations of the cytoarchitecture of brain cortex, subcortical structures and cerebellum observed in individuals with autism.43 Consequently, the decrease in expression of mitochondrial enzymes observed in our array (Table 1) may represent a compensatory mechanism to contain Ca2+ overload-induced apoptosis in these cells. It has already been reported that compromised mitochondria accumulate (observed by increased mitochondrial mass) in pyramidal neurons in temporal cortex of younger ASD subjects.44 Moreover, PSEN1 and PSEN2 are believed to have almost overlapping cellular functions and contribute to diverse physiological processes, such as regulation of Ca2+ homeostasis, protein transport and turnover, autophagy, cell adhesion, neurotransmitter release, and axon guidance.45 PSEN2, however, seems to be responsible for endoplasmic reticulum (ER) and mitochondria interactions.46 Closer ER–mitochondria juxtaposition (regulated by PSEN2) may expose mitochondria to excessive Ca2+ stimulation, triggering the apoptotic cascade by mitochondria Ca2+ overload. In our array analysis, we found that PSEN2 is downregulated (corrected P-value=0.005968353) in the cerebellum of autistic patients (Table 1), which could represent another compensatory mechanism to reduce Ca2+ overload-induced apoptosis. Our hypothesis is further supported by the following observations: (i) mutant mice in which glutamate receptors are overstimulated by knocking out (KO) glutamate transporters GLAST and GLT1, and thus leading to excessive glutamatergic signaling in the prenatal stage, compromising early brain development via overstimulation of NMDARs. NR1 deletion in double KO mice almost completely rescued multiple brain defects including cortical, hippocampal, and olfactory bulb disorganization and defective corticothalamic and thalamocortical axonal projections;47 (ii) opposite to what it is seen in AD patients, higher levels of sAPPα have been described in plasma from autistic children when compared with controls, favoring an increased α-secretase pathway;12, 48 (iii) evidence of autoimmunity and persistent systemic immune activation have been reported in ASD,49 and mice overexpressing human sAPPα indeed exhibit higher T-cell cytokine secretion together with reduced CD4+ and higher CD8+ T-cell populations in splenocytes when compared with wild-type animals. These animals also display hypoactivity, impaired social interaction, elevated levels of brain glial fibrillary acidic protein (GFAP) expression, and altered Notch1 and interleukin-6 levels.50 In the brain of autistic individuals, increased expression of GFAP in the areas with disturbed neuronal architecture has been detected together with interleukin-6, interleukin-8, tumor necrosis factor-α, interferon-γ, and granulocyte–macrophage colony-stimulating factor, suggesting astrogliotic response and potential alterations in neurogenesis and neuronal migration.51, 52, 53, 54 (iv) Finally, we observed a significant decrease (corrected P-value=0.024237411) in expression of APBB1 (Aβ A4 precursor protein binding, family B, member 1; or F65) (Table 1). In vitro F65 overexpression induces a marked increase in Aβ secretion, whereas Aβ secretion is decreased in Fe65 knockdown cells and also in hippocampal neurons of Fe65/Fe65L1 KO mice.55, 56, 57

Figure 6.

Figure 6

Open in a new tab

Hypothetical model of the synaptic mechanism regulating Aβ production and the link to aberrant brain growth and connectivity in autism. The development of living organisms parallels to a so-called physiological ‘intrinsic developmental stress', which is associated to massive internal changes during morphogenesis, and thus contributes to the time window of vulnerability to the environment. Development and severity of ASD are likely to arise from complex interactions between pre-existing genetic vulnerability/ies in these children, the exposure to noxious environmental factors, and the timing of the stressful event(s); given that prenatal life, infancy, childhood, and adolescence are critical periods characterized by increased vulnerability to stressors.2, 3 Glial activation and neuroinflammation seem to persist during adulthood in autism, and early brain overgrowth in autism could be a consequence of an over-activation of neural proliferation in a trial to compensate the cellular loss induced by environmental stress/ors, triggering precipitous/uncontrolled migration and misdistribution of neurons among different brain areas. Our model proposed that aberrant epigenetic regulation may lead to increased density of NMDA receptors and, therefore, to increased Ca+2 entry and stimulation of ERK-dependent α-secretase activity. The decrease in mitochondrial enzymatic activity together with the downregulation of PSEN2 at the ER may represent a compensatory mechanism to reduce the Ca2+ overload-induced apoptosis. PSEN2 downregulation may diminish the interaction between ER and mitochondria, reducing its Ca+2 uptake. In turn, mitochondrial mass would increase most likely to maintain the cellular ATP levels. Higher levels of sAPPα would activate the PI3K/Akt/mTOR pathway resulting in proliferation, aberrant brain growth, and disruption of synaptic plasticity and connectome

Systems pharmacology analyses of NOWADA network revealed that Mg2+ and rapamycin could efficiently target this pathway in silico, when compared to other drugs (Supplementary Table S10). RhoGAPs, regulatory molecules of RHO GTPases (e.g., CDC42, RHOA, and RAC1), which altered expression were shown in autism,3 use Mg2+ as a cofactor to reach catalytic efficiency and specificity in GTP hydrolysis (Supplementary Table S11).58 Furthermore, GSK3B, a HB in our network model (Supplementary Table S6), is a ubiquitous serine/threonine kinase that catalyzes the transfer of γ-phosphate of ATP to the hydroxyl oxygen of the Ser and Thr residues of a kinase-specific protein substrate is a Mg2+-dependent kinase.59 Its aberrant function has been linked to diverse neurological disorders such as AD.60 Lower concentrations of Mg2+ were described in children with autism.61 Similarly, in AD patients, Mg2+ concentrations in the brain seem to be significantly lower when compared with age-matched normal individuals.62 Recently, it was suggested that elevation of brain Mg2+ concentration in the brain exerts substantial synaptoprotective effects in an in vivo model of AD, and hence Mg2+ may have therapeutic potential for treating AD in humans.17 In autism, positive behavioral effects of combined Mg2+ and pyridoxine treatment were described;63 combination that was also proposed to be beneficial in ASD patients that experience seizures.64 The therapeutic usage of rapamycin (mTOR inhibitor) in ASD is nowadays discussed. TSC1 and TSC2 are upstream inhibitory regulators of mTOR activity, and studies performed in TSC2+/− mice showed that treatment with rapamycin can rescue synaptic plasticity and reverse the abnormal late phase of long-term potentiation.20 These results encourage future clinical trials with TOR inhibitors as pharmacological treatment of ASD.

We believe that the computational analyses performed in this study gave valuable clues to (i) develop a model that may explain the aberrant brain overgrowth and impaired neuronal connectivity observed in these children; and (ii) refer to the need of further therapeutic exploration of Mg2+- and rapamycin-based treatments in animal models and clinical trials with autistic patients.

Materials and Methods

Development of gene/protein network models

NOTCH, WNT, AD, and apoptosis subnetwork models were developed through (i) extracting the information provided by the KEGG PATHWAY database (http://www.genome.jp/kegg/pathway.html; NOTCH pathway: map04330, WNT pathway: map 04310; AD pathway: map05010, and apoptosis pathway: map04210); and (ii) by establishing the interactions between genes/proteins with the database resource Search Tool for the Retrieval of Interacting Genes/Proteins STRING version 9.05 (http://string-db.org/); with ‘Experiments' and ‘Databases' as input options and a confidence score of 0.600. STRING is a well-known public database with information about direct and indirect functional protein–protein interactions. The genes/proteins belonging to NOTCH, WNT, AD, and apoptosis subnetwork models were identified by the HUGO Gene Symbol65 and Ensemble protein ID (Supplementary Tables S1–S4). Once they were selected, the links between two different nodes (genes/proteins), provided by the STRING database, are saved in data files to be processed in the Medusa interface66 and visualized as a subnetwork (NOTCH, WNT, AD, or apoptosis). The Venn diagram was constructed by using the freely available software system R (http://www.r-project.org)67 in order to visualize the grade of molecular relation (common genes/proteins) between the generated subnetworks. The in silico network model integrating NOTCH, WNT, AD, and apoptosis subnetworks (NOWADA) was developed by using again STRING version 9.05 with ‘Experiments' and ‘Databases' as input options and a confidence score of 0.600 (0.400 is considered ‘medium confidence') and plotted by using Cytoscape, an open source platform for complex network analysis and visualization (http://www.cytoscape.org/).68

Data acquisition and processing, determination of variably expressed genes, statistics, and gene expression network visualization

Microarray data (raw data;.cel files) were obtained from the Geo DataSets database (http://www.ncbi.nlm.nih.gov/geo/). The data set (GSE38322), originally contributed by Ginsberg et al.,69 is publicly available; it contains data from cerebellar brain tissue of autistic patients and control subjects. Experimental assays are described in full in the original publication and details include the selection criteria of patients (both inclusion and exclusion criteria) and diagnostic profile.69 For elucidating the differential expression of members from the NOTCH, WNT, AD, and apoptosis subnetworks, expression data were filtered from probes with <0.05 signal detection P-values and normalized by using the lumi package from R and robust spline normalization. For differential gene expression analysis, normalized data of cerebellar samples from patients versus controls were analyzed by using the limma package from R67 and false discovery rate (FDR) control for statistical assessment of the microarray data (corrected P-values <0.05 were considered significant). Specific corrected P-values for each differentially expressed gene are provided (Table 1). In order to visualize the general landscape of gene expression in silico, gene expression in samples from autism were plotted versus the expression found in healthy controls to be visualized with the ViaComplex software, a tool that was previously developed and validated in our laboratory.70 This software plots gene expression over the Medusa network (in a color scale) by overlapping functional input data (microarray expression data) with interaction information (NOTCH, WNT, AD, and apoptosis subnetworks) and distributes the microarray signal according to the coordinates of the nodes and its interactions in the network of interest.

Elucidation of network centralities to predict the relevance of genes in the overall network architecture

Topological network properties of the genes/proteins integrating the network (NOWADA) were calculated by using Cytoscape.68 Numeric values corresponding to the properties of each node are additionally provided (Supplementary Table S5). Thresholds for selection criteria of the most relevant nodes according to their centrality values were established considering one s.d. of the mean for each topological network properties: ‘stress': 48 919.44 (mean=15251.9); ‘connectivity or degree': 35.84815 (mean=19.59893); ‘betweenness': 0.022270086 (mean=0.005765439); and ‘closeness': 0.372488254 (mean=0.325097663). Centrality values were plotted in graphs by using OriginLab (http://www.originlab.com/index.aspx?go=Products/OriginPro). Nodes (genes/proteins) with high connectivity (above the threshold) and low betweenness centrality (below the threshold) are considered hub-non-bottlenecks and those ones with a value above the thresholds for both connectivity and betweenness centrality are referred to as HBs. Similarly, non-HBs (NH-Bs) are nodes with low connectivity and high betweenness centrality, and non-hub-non-bottlenecks are nodes with both connectivity and betweenness centrality values below the thresholds.18

In silico development of compound (drug)-gene/protein network model

To construct the compound (drug)-gene/protein network models, we first performed a systematic review of relevant literature associated with autism or AD therapy in the PubMed database (http://www.ncbi.nlm.nih.gov/pubmed/). These articles were obtained by using the two terms ‘autism' and ‘ASD' and combining them with the following terms: ‘Alzheimer's disease', ‘therapy', ‘therapeutics', ‘treatment', and/or ‘drug', respectively. Moreover, compound identifier, formula, description, and selected autism- and AD-related reports (with PMID) for these drugs (Supplementary Table S6) are additionally provided with KEGG DRUG (http://www.genome.jp/kegg/drug/), the Search Tool for Interactions of Chemicals STITCH version 3.1 (http://stitch.embl.de/), and PubMed database as sources of information. Second, these drugs were submitted to in silico analysis by searching the number of genes/proteins within NOWADA network that are targeted by the selected drugs. To achieve this goal, STITCH version 3.1 (http://stitch.embl.de/) was used with ‘Experiments' and ‘Databases' as input options and a confidence score of 0.600 (0.400 is considered ‘medium confidence'). A list with the most drug-targeted network nodes (genes/proteins) is also provided (Supplementary Table S8). Again, the links between two different nodes (drug-genes/proteins), provided by the STITCH database, is saved in data files to be handled in the Medusa interface and visualized as a subnetwork. For screening potential cellular targets of the most drug-targeted network nodes (NOWADA), another systematic review of both original research articles and reviews was performed in PubMed database. These articles were obtained by using the genes/proteins name or symbol and combining them with the following terms: ‘Neuronal', ‘Neuron', ‘Astroglia', ‘Astrocyte', ‘Microglia', ‘Oligodendroglia', and/or ‘Oligodendrocyte' (Supplementary Table S9).The selected references confirm the expression of the indicated gene products in brain cells. Note that the selected references do not cover therapeutic modalities, age or brain region specificity.

Functional enrichment analysis (biological processes)

The biological processes of the genes products belonging to the subnetwork model of interactions was determined by using the database for annotation, visualization, and integrated discovery DAVID v6.7 (http://david.abcc.ncifcrf.gov/), giving a number of functional annotation tools to researchers for better comprehension of the biological meaning behind any large list of genes. Only those biological processes with corrected P-value <0.05 (FDR) were selected. Specific corrected P-values for each biological process are provided (Supplementary Table S9).

A graphical abstract, summarizing the contents and the methodological approaches used for the present study, is also provided (Figure 7).

Figure 7.

Figure 7

Open in a new tab

Abstract workflow summarizing the different approaches used for the present study. The information from the different pathways (NOTCH, WNT, AD, and apoptosis) was gathered from KEGG pathway (http://www.genome.jp/kegg/pathway.html) to develop the subnetworks. The differential expression of the genes belonging to each subnetwork was analyzed in the cerebellum of autistic patients by using R. A Venn diagram showed common genes/proteins between NOTCH, WNT, AD, and apoptosis pathways. Thereafter, a network model was developed for integrating these subnetworks into one single gene/protein interaction network model (NOWADA network) by using STRING 9.05 and Cytoscape tools. Further elucidation of the topological network properties revealed a number of potential molecular targets or ‘vulnerable' points of the in silico model and therapeutic agents used in autism targeting central nodes of the network were studied (STITCH 3.1). Finally, a subnetwork representing the interaction between Mg2+ and genes/proteins from NOWADA network was constructed and a functional enrichment analysis was performed (DAVID v6.7) to elucidate the biological processes potentially affected by this compound

Acknowledgments

First of all, our sincere apologies to the authors whose work have not been cited in the present study because of space considerations. We thank Brazilian research funding agencies FAPERGS (PqG 1008860, PqG 1008857, ARD11/1893-7, and PRONEX 1000274), CAPES (PROCAD 066/2007), CNPq (558289/2008-8 and 302330/2009-7), as well as PROPESQ-UFRGS for supporting this work.

Glossary

Aβ

amyloid-β

AD

Alzheimer's disease

APP

amyloid-β precursor protein

ASD

autism spectrum disorder

ER

endoplasmic reticulum

FDR

false discovery rate

GFAP

glial fibrillary acidic protein

HBs

hub-bottlenecks

IGF-1

insulin growth factor 1

IGF-2

insulin growth factor 2

NH-Bs

non-hub-bottlenecks

sAPPα

secreted amyloid-β precursor protein α

sAPPβ

secreted amyloid-β precursor protein β

The authors declare no conflict of interest.

Footnotes

Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)

Edited by D Bano

Supplementary Material

Supplementary Figure S1
Click here for additional data file. (3.8MB, tif)
Supplementary Figure S2
Click here for additional data file. (7.6MB, tif)
Supplementary Figure S3
Click here for additional data file. (4.2MB, tif)
Supplementary Table S1
Click here for additional data file. (57KB, doc)
Supplementary Table S2
Click here for additional data file. (141.5KB, doc)
Supplementary Table S3
Click here for additional data file. (171.5KB, doc)
Supplementary Table S4
Click here for additional data file. (82KB, doc)
Supplementary Table S5
Click here for additional data file. (506KB, doc)
Supplementary Table S6
Click here for additional data file. (259KB, doc)
Supplementary Table S7
Click here for additional data file. (169.5KB, doc)
Supplementary Table S8
Click here for additional data file. (61.5KB, doc)
Supplementary Table S9
Click here for additional data file. (42.5KB, doc)
Supplementary Table S10
Click here for additional data file. (47.5KB, doc)
Supplementary Table S11
Click here for additional data file. (153.5KB, doc)

References

  1. Casanova MF. The neuropathology of autism. Brain Pathol. 2007;17:422–423. doi: 10.1111/j.1750-3639.2007.00100.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Zeidán-Chuliá F, Gursoy UK, Könönen E, Gottfried C. A dental look at the autistic patient through orofacial pain. Acta Odontol Scand. 2011;69:193–200. doi: 10.3109/00016357.2010.549505. [DOI] [PubMed] [Google Scholar]
  3. Zeidán-Chuliá F, Rybarczyk-Filho JL, Salmina AB, de Oliveira BH, Noda M, Moreira JC. Exploring the multifactorial nature of autism through computational systems biology: calcium and the Rho GTPase RAC1 under the spotlight. Neuromolecular Med. 2013;15:364–383. doi: 10.1007/s12017-013-8224-3. [DOI] [PubMed] [Google Scholar]
  4. Courchesne E, Carper R, Akshoomoff N. Evidence of brain overgrowth in the first year of life in autism. JAMA. 2003;290:337–344. doi: 10.1001/jama.290.3.337. [DOI] [PubMed] [Google Scholar]
  5. Miyazaki K, Narita N, Sakuta R, Miyahara T, Naruse H, Okado N, et al. Serum neurotrophin concentrations in autism and mental retardation: a pilot study. Brain Dev. 2004;26:292–295. doi: 10.1016/S0387-7604(03)00168-2. [DOI] [PubMed] [Google Scholar]
  6. Mills JL, Hediger ML, Molloy CA, Chrousos GP, Manning-Courtney P, Yu KF, et al. Elevated levels of growth-related hormones in autism and autism spectrum disorder. Clin Endocrinol (Oxf) 2007;67:230–237. doi: 10.1111/j.1365-2265.2007.02868.x. [DOI] [PubMed] [Google Scholar]
  7. Ricci S, Businaro R, Ippoliti F, Lo Vasco VR, Massoni F, Onofri E, et al. Altered cytokine and BDNF levels in autism spectrum disorder. Neurotox Res. 2013;24:491–501. doi: 10.1007/s12640-013-9393-4. [DOI] [PubMed] [Google Scholar]
  8. Zeidán-Chuliá F, Salmina AB, Malinovskaya NA, Noda M, Verkhratsky A, Moreira JC. The glial perspective of autism spectrum disorders. Neurosci Biobehav Rev. 2014;38:160–172. doi: 10.1016/j.neubiorev.2013.11.008. [DOI] [PubMed] [Google Scholar]
  9. Braak H, de Vos RA, Jansen EN, Bratzke H, Braak E. Neuropathological hallmarks of Alzheimer's and Parkinson's diseases. Prog Brain Res. 1998;117:267–285. doi: 10.1016/s0079-6123(08)64021-2. [DOI] [PubMed] [Google Scholar]
  10. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741–766. doi: 10.1152/physrev.2001.81.2.741. [DOI] [PubMed] [Google Scholar]
  11. Rodríguez JJ, Verkhratsky A. Neurogenesis in Alzheimer's disease. J Anat. 2011;219:78–89. doi: 10.1111/j.1469-7580.2011.01343.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ray B, Long JM, Sokol DK, Lahiri DK. Increased secreted amyloid precursor protein-α (sAPPα) in severe autism: proposal of a specific, anabolic pathway and putative biomarker. PLoS One. 2011;6:e20405. doi: 10.1371/journal.pone.0020405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Courchesne E, Redcay E, Morgan JT, Kennedy DP. Autism at the beginning: microstructural and growth abnormalities underlying the cognitive and behavioral phenotype of autism. Dev Psychopathol. 2005;17:577–597. doi: 10.1017/S0954579405050285. [DOI] [PubMed] [Google Scholar]
  14. Reeber SL, Otis TS, Sillitoe RV. New roles for the cerebellum in health and disease. Front Syst Neurosci. 2013;7:83. doi: 10.3389/fnsys.2013.00083. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rogers TD, McKimm E, Dickson PE, Goldowitz D, Blaha CD, Mittleman G. Is autism a disease of the cerebellum? An integration of clinical and pre-clinical research. Front Syst Neurosci. 2013;7:15. doi: 10.3389/fnsys.2013.00015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Cai Z, Zhao B, Li K, Zhang L, Li C, Quazi SH, et al. Mammalian target of rapamycin: a valid therapeutic target through the autophagy pathway for Alzheimer's disease. J Neurosci Res. 2012;90:1105–1118. doi: 10.1002/jnr.23011. [DOI] [PubMed] [Google Scholar]
  17. Li W, Yu J, Liu Y, Huang X, Abumaria N, Zhu Y, et al. Elevation of brain magnesium prevents and reverses cognitive deficits and synaptic loss in Alzheimer's disease mouse model. J Neurosci. 2013;33:8423–8441. doi: 10.1523/JNEUROSCI.4610-12.2013. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  18. Rosado JO, Henriques JP, Bonatto D. A systems pharmacology analysis of major chemotherapy combination regimens used in gastric cancer treatment: Predicting potential new protein targets and drugs. Curr Cancer Drug Targets. 2011;11:849–869. doi: 10.2174/156800911796798977. [DOI] [PubMed] [Google Scholar]
  19. Kerbeshian J, Burd L, Fisher W. Lithium carbonate in the treatment of two patients with infantile autism and atypical bipolar symptomatology. J Clin Psychopharmacol. 1987;7:401–405. [PubMed] [Google Scholar]
  20. Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, et al. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med. 2008;14:843–848. doi: 10.1038/nm1788. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One. 2010;5:e9979. doi: 10.1371/journal.pone.0009979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Curr Alzheimer Res. 2013;10:104–107. doi: 10.2174/1567205011310010014. [DOI] [PubMed] [Google Scholar]
  23. Lahiri DK, Sokol DK, Erickson C, Ray B, Ho CY, Maloney B. Autism as early neurodevelopmental disorder: evidence for an sAPPα-mediated anabolic pathway. Front Cell Neurosci. 2013;7:94. doi: 10.3389/fncel.2013.00094. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y, Jacobson MD. Programmed cell death and the control of cell survival: lessons from the nervous system. Science. 1993;262:695–700. doi: 10.1126/science.8235590. [DOI] [PubMed] [Google Scholar]
  25. Zhang H, Ma Q, Zhang YW, Xu H. Proteolytic processing of Alzheimer's β-amyloid precursor protein. J Neurochem. 2012;120 (Suppl 1:9–21. doi: 10.1111/j.1471-4159.2011.07519.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Kojro E, Postina R. Regulated proteolysis of RAGE and AbetaPP as possible link between type 2 diabetes mellitus and Alzheimer's disease. J Alzheimers Dis. 2009;16:865–878. doi: 10.3233/JAD-2009-0998. [DOI] [PubMed] [Google Scholar]
  27. Yu W, Mechawar N, Krantic S, Quirion R. Evidence for the involvement of apoptosis-inducing factor-mediated caspase-independent neuronal death in Alzheimer disease. Am J Pathol. 2010;176:2209–2218. doi: 10.2353/ajpath.2010.090496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Mattson MP. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev. 1997;77:1081–1132. doi: 10.1152/physrev.1997.77.4.1081. [DOI] [PubMed] [Google Scholar]
  29. Ohsawa I, Takamura C, Morimoto T, Ishiguro M, Kohsaka S. Amino-terminal region of secreted form of amyloid precursor protein stimulates proliferation of neural stem cells. Eur J Neurosci. 1999;11:1907–1913. doi: 10.1046/j.1460-9568.1999.00601.x. [DOI] [PubMed] [Google Scholar]
  30. Caillé I, Allinquant B, Dupont E, Bouillot C, Langer A, Müller U, et al. Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development. 2004;131:2173–2181. doi: 10.1242/dev.01103. [DOI] [PubMed] [Google Scholar]
  31. Gakhar-Koppole N, Hundeshagen P, Mandl C, Weyer SW, Allinquant B, Müller U, et al. Activity requires soluble amyloid precursor protein alpha to promote neurite outgrowth in neural stem cell-derived neurons via activation of the MAPK pathway. Eur J Neurosci. 2008;28:871–882. doi: 10.1111/j.1460-9568.2008.06398.x. [DOI] [PubMed] [Google Scholar]
  32. Young-Pearse TL, Bai J, Chang R, Zheng JB, LoTurco JJ, Selkoe DJ. A critical function for beta-amyloid precursor protein in neuronal migration revealed by in utero RNA interference. J Neurosci. 2007;27:14459–1469. doi: 10.1523/JNEUROSCI.4701-07.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Boo JH, Sohn JH, Kim JH, Song H, Mook-Jung I. Rac1 changes the substrate specificity of gamma-secretase between amyloid precursor protein and Notch1. Biochem Biophys Res Commun. 2008;372:913–917. doi: 10.1016/j.bbrc.2008.05.153. [DOI] [PubMed] [Google Scholar]
  34. Woo HN, Park JS, Gwon AR, Arumugam TV, Jo DG. Alzheimer's disease and Notch signaling. Biochem Biophys Res Commun. 2009;390:1093–1097. doi: 10.1016/j.bbrc.2009.10.093. [DOI] [PubMed] [Google Scholar]
  35. Guevara-Campos J, González-Guevara L, Puig-Alcaraz C, Cauli O. Autism spectrum disorders associated to a deficiency of the enzymes of the mitochondrial respiratory chain. Metab Brain Dis. 2013;28:605–612. doi: 10.1007/s11011-013-9419-x. [DOI] [PubMed] [Google Scholar]
  36. Lee SF, Srinivasan B, Sephton CF, Dries DR, Wang B, Dewey CM, et al. Gamma-secretase-regulated proteolysis of the Notch receptor by mitochondrial intermediate peptidase. J Biol Chem. 2011;286:27447–27453. doi: 10.1074/jbc.M111.243154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Yujiri T, Sather S, Fanger GR, Johnson GL. Role of MEKK1 in cell survival and activation of JNK and ERK pathways defined by targeted gene disruption. Science. 1998;282:1911–1914. doi: 10.1126/science.282.5395.1911. [DOI] [PubMed] [Google Scholar]
  38. Tavassoli E, Saboory E, Teshfam M, Rasmi Y, Roshan-Milani S, Ilkhanizadeh B, et al. Effect of prenatal stress on density of NMDA receptors in rat brain. Int J Dev Neurosci. 2013;31:790–795. doi: 10.1016/j.ijdevneu.2013.09.010. [DOI] [PubMed] [Google Scholar]
  39. Stadler F, Kolb G, Rubusch L, Baker SP, Jones EG, Akbarian S. Histone methylation at gene promoters is associated with developmental regulation and region-specific expression of ionotropic and metabotropic glutamate receptors in human brain. J Neurochem. 2005;94:324–336. doi: 10.1111/j.1471-4159.2005.03190.x. [DOI] [PubMed] [Google Scholar]
  40. Verges DK, Restivo JL, Goebel WD, Holtzman DM, Cirrito JR. Opposing synaptic regulation of amyloid-β metabolism by NMDA receptors in vivo. J Neurosci. 2011;31:11328–11337. doi: 10.1523/JNEUROSCI.0607-11.2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Cheng G, Yu Z, Zhou D, Mattson MP. Phosphatidylinositol-3-kinase-Akt kinase and p42/p44 mitogen-activated protein kinases mediate neurotrophic and excitoprotective actions of a secreted form of amyloid precursor protein. Exp Neurol. 2002;175:407–414. doi: 10.1006/exnr.2002.7920. [DOI] [PubMed] [Google Scholar]
  42. Demars MP, Bartholomew A, Strakova Z, Lazarov O. Soluble amyloid precursor protein: a novel proliferation factor of adult progenitor cells of ectodermal and mesodermal origin. Stem Cell Res Ther. 2011;2:36. doi: 10.1186/scrt77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Wegiel J, Kuchna I, Nowicki K, Imaki H, Wegiel J, Marchi E, et al. The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes. Acta Neuropathol. 2010;119:755–770. doi: 10.1007/s00401-010-0655-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Tang G, Gutierrez Rios P, Kuo SH, Akman HO, Rosoklija G, Tanji K, et al. Mitochondrial abnormalities in temporal lobe of autistic brain. Neurobiol Dis. 2013;54:349–361. doi: 10.1016/j.nbd.2013.01.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Zampese E, Fasolato C, Pozzan T, Pizzo P. Presinilin-2 modulation of ER-mitochondria interactions: FAD mutations, mechanisms and pathological consequences. Commun Integr Biol. 2011;4:357–360. doi: 10.4161/cib.4.3.15160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Zampese E, Fasolato C, Kipanyula MJ, Bortolozzi M, Pozzan T, Pizzo P. Presenilin 2 modulates endoplasmic reticulum (ER)-mitochondria interactions and Ca2+ cross-talk. Proc Natl Acad Sci USA. 2011;108:2777–2782. doi: 10.1073/pnas.1100735108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Aida T, Ito Y, Takahashi YK, Tanaka K. Overstimulation of NMDA receptors impairs early brain development in vivo. PLoS One. 2012;7:e36853. doi: 10.1371/journal.pone.0036853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Sokol DK, Chen D, Farlow MR, Dunn DW, Maloney B, Zimmer JA, et al. High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression. J Child Neurol. 2006;21:444–449. doi: 10.1177/08830738060210062201. [DOI] [PubMed] [Google Scholar]
  49. Ashwood P, Van de Water J. Is autism an autoimmune disease. Autoimmun Rev. 2004;3:557–562. doi: 10.1016/j.autrev.2004.07.036. [DOI] [PubMed] [Google Scholar]
  50. Bailey AR, Hou H, Song M, Obregon DF, Portis S, Barger S, et al. GFAP expression and social deficits in transgenic mice overexpressing human sAPPα. Glia. 2013;61:1556–1569. doi: 10.1002/glia.22544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Laurence JA, Fatemi SH. Glial fibrillary acidic protein is elevated in superior frontal, parietal and cerebellar cortices of autistic subjects. Cerebellum. 2005;4:206–210. doi: 10.1080/14734220500208846. [DOI] [PubMed] [Google Scholar]
  52. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005;57:67–81. doi: 10.1002/ana.20315. [DOI] [PubMed] [Google Scholar]
  53. Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li XM, et al. Elevated immune response in the brain of autistic patients. J Neuroimmunol. 2009;207:111–116. doi: 10.1016/j.jneuroim.2008.12.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Wei H, Zou H, Sheikh AM, Malik M, Dobkin C, Brown WT, et al. IL-6 is increased in the cerebellum of autistic brain and alters neural cell adhesion, migration and synaptic formation. J Neuroinflammation. 2011;8:52. doi: 10.1186/1742-2094-8-52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Sabo SL, Lanier LM, Ikin AF, Khorkova O, Sahasrabudhe S, Greengard P, et al. Regulation of beta-amyloid secretion by FE65, an amyloid protein precursor-binding protein. J Biol Chem. 1999;274:7952–7957. doi: 10.1074/jbc.274.12.7952. [DOI] [PubMed] [Google Scholar]
  56. Xie Z, Dong Y, Maeda U, Xia W, Tanzi RE. RNA interference silencing of the adaptor molecules ShcC and Fe65 differentially affect amyloid precursor protein processing and Abeta generation. J Biol Chem. 2007;282:4318–4325. doi: 10.1074/jbc.M609293200. [DOI] [PubMed] [Google Scholar]
  57. Suh J, Lyckman A, Wang L, Eckman EA, Guénette SY. FE65 proteins regulate NMDA receptor activation-induced amyloid precursor protein processing. J Neurochem. 2011;119:377–388. doi: 10.1111/j.1471-4159.2011.07419.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Zhang B, Zhang Y, Wang Z, Zheng Y. The role of Mg2+ cofactor in the guanine nucleotide exchange and GTP hydrolysis reactions of Rho family GTP-binding proteins. J Biol Chem. 2000;275:25299–25307. doi: 10.1074/jbc.M001027200. [DOI] [PubMed] [Google Scholar]
  59. Lu SY, Huang ZM, Huang WK, Liu XY, Chen YY, Shi T, et al. How Calcium inhibits the magnesium-dependent kinase gsk3β: a molecular simulation study. Proteins. 2013;81:740–753. doi: 10.1002/prot.24221. [DOI] [PubMed] [Google Scholar]
  60. He P, Shen Y. Interruption of beta-catenin signaling reduces neurogenesis in Alzheimer's disease. J Neurosci. 2009;29:6545–6557. doi: 10.1523/JNEUROSCI.0421-09.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Strambi M, Longini M, Hayek J, Berni S, Macucci F, Scalacci E, et al. Magnesium profile in autism. Biol Trace Elem Res. 2006;109:97–104. doi: 10.1385/BTER:109:2:097. [DOI] [PubMed] [Google Scholar]
  62. Andrási E, Páli N, Molnár Z, Kösel S. Brain aluminum, magnesium and phosphorus contents of control and Alzheimer-diseased patients. J Alzheimers Dis. 2005;7:273–284. doi: 10.3233/jad-2005-7402. [DOI] [PubMed] [Google Scholar]
  63. Lelord G, Muh JP, Barthelemy C, Martineau J, Garreau B, Callaway E. Effects of pyridoxine and magnesium on autistic symptoms—initial observations. J Autism Dev Disord. 1981;11:219–230. doi: 10.1007/BF01531686. [DOI] [PubMed] [Google Scholar]
  64. Frye RE, Rossignol D, Casanova MF, Brown GL, Martin V, Edelson S, et al. A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel. Front Public Health. 2013;1:31. doi: 10.3389/fpubh.2013.00031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Wain HM, Lush MJ, Ducluzeau F, Khodiyar VK, Povey S. Genew: The Human Gene Nomenclature Database, 2004 updates. Nucleic Acids Res. 2004;32:D255–D257. doi: 10.1093/nar/gkh072. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Hooper SD, Bork P. Medusa: a simple tool for interaction graph analysis. Bioinformatics. 2005;21:4432–4433. doi: 10.1093/bioinformatics/bti696. [DOI] [PubMed] [Google Scholar]
  67. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80. doi: 10.1186/gb-2004-5-10-r80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011;27:431–432. doi: 10.1093/bioinformatics/btq675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Ginsberg MR, Rubin RA, Falcone T, Ting AH, Natowicz MR. Brain transcriptional and epigenetic associations with autism. PLoS One. 2012;7:e44736. doi: 10.1371/journal.pone.0044736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Castro MA, Filho JL, Dalmolin RJ, Sinigaglia M, Moreira JC, Mombach JC, et al. Viacomplex: software for landscape analysis of gene expression networks in genomic context. Bioinformatics. 2009;25:1468–1469. doi: 10.1093/bioinformatics/btp246. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Figure S1
Click here for additional data file. (3.8MB, tif)
Supplementary Figure S2
Click here for additional data file. (7.6MB, tif)
Supplementary Figure S3
Click here for additional data file. (4.2MB, tif)
Supplementary Table S1
Click here for additional data file. (57KB, doc)
Supplementary Table S2
Click here for additional data file. (141.5KB, doc)
Supplementary Table S3
Click here for additional data file. (171.5KB, doc)
Supplementary Table S4
Click here for additional data file. (82KB, doc)
Supplementary Table S5
Click here for additional data file. (506KB, doc)
Supplementary Table S6
Click here for additional data file. (259KB, doc)
Supplementary Table S7
Click here for additional data file. (169.5KB, doc)
Supplementary Table S8
Click here for additional data file. (61.5KB, doc)
Supplementary Table S9
Click here for additional data file. (42.5KB, doc)
Supplementary Table S10
Click here for additional data file. (47.5KB, doc)
Supplementary Table S11
Click here for additional data file. (153.5KB, doc)

Articles from Cell Death & Disease are provided here courtesy of Nature Publishing Group

RESOURCES